Physician profile
Luis Mora
NPI 1356576961
$1,490.57
in general payments reported to CMS, 2019-2025
11 companies · $493 in 2025
The $493 reported for 2025 was more than what a typical Foot Surgery provider received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $261 · 2021: $71.59 · 2023: $57.01 · 2024: $393 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $943.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $398.28 | 2019-2023 | Jublia |
| Amgen INC. | $367.91 | 2024-2025 | Krystexxa |
| Advanced Oxygen Therapy INC. | $286.71 | 2024-2025 | Topical Oxygen Chamber For Extremities |
| Celularity INC. | $114.00 | 2019 | |
| Paratek Pharmaceuticals, INC. | $93.06 | 2024 | Nuzyra |
| Treace Medical Concepts, INC. | $68.27 | 2024-2025 | |
| Polynovo North America LLC | $48.15 | 2025 | Novosorb Btm |
| Stryker Corporation | $39.35 | 2021 | |
| Smith+Nephew, INC. | $37.60 | 2023-2024 | Collagenase Santyl |
| Melinta Therapeutics, LLC | $18.87 | 2021 | |
| Sebela Pharmaceuticals INC. | $18.37 | 2023 | Naftin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Mora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.